BeiGene Future Growth
Future criteria checks 4/6
BeiGene is forecast to grow earnings and revenue by 56.2% and 19.4% per annum respectively. EPS is expected to grow by 60.1% per annum. Return on equity is forecast to be 13.6% in 3 years.
Key information
56.2%
Earnings growth rate
60.1%
EPS growth rate
| Biotechs earnings growth | 21.2% |
| Revenue growth rate | 19.4% |
| Future return on equity | 13.6% |
| Analyst coverage | Good |
| Last updated | 19 Apr 2024 |
Recent future growth updates
Recent updates
Is BeiGene (NASDAQ:BGNE) Using Too Much Debt?
Apr 21
BeiGene Still Bleeding Red Ink Despite Blockbuster Drug
Mar 08BeiGene, Ltd.'s (NASDAQ:BGNE) Intrinsic Value Is Potentially 26% Above Its Share Price
Jan 31Here's Why BeiGene (NASDAQ:BGNE) Can Manage Its Debt Despite Losing Money
Oct 16Is There An Opportunity With BeiGene, Ltd.'s (NASDAQ:BGNE) 39% Undervaluation?
Jul 11Rock star Growth Puts BeiGene (NASDAQ:BGNE) In A Position To Use Debt
Jun 19Revenues Not Telling The Story For BeiGene, Ltd. (NASDAQ:BGNE)
Apr 17A Look At The Fair Value Of BeiGene, Ltd. (NASDAQ:BGNE)
Mar 24Is BeiGene (NASDAQ:BGNE) Using Debt Sensibly?
Dec 07BeiGene upgraded to buy at Guggenheim on improved confidence in Brukinsa potential
Oct 13EMA panel recommends extending indication for BeiGene's cancer drug Brukinsa
Sep 16Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 4,883 | 344 | 411 | 808 | 18 |
| 12/31/2025 | 3,925 | -358 | -424 | -82 | 28 |
| 12/31/2024 | 3,081 | -892 | -890 | -663 | 29 |
| 12/31/2023 | 2,459 | -882 | -1,754 | -1,157 | N/A |
| 9/30/2023 | 2,204 | -959 | -1,853 | -1,254 | N/A |
| 6/30/2023 | 1,811 | -1,732 | -2,283 | -1,738 | N/A |
| 3/31/2023 | 1,557 | -1,917 | -2,298 | -1,824 | N/A |
| 12/31/2022 | 1,416 | -2,004 | -1,966 | -1,497 | N/A |
| 9/30/2022 | 1,250 | -2,149 | -2,144 | -1,686 | N/A |
| 6/30/2022 | 1,069 | -2,030 | -2,016 | -1,620 | N/A |
| 3/31/2022 | 877 | -1,960 | -2,044 | -1,660 | N/A |
| 12/31/2021 | 1,176 | -1,458 | -1,614 | -1,299 | N/A |
| 9/30/2021 | 1,062 | -1,340 | -1,334 | -1,123 | N/A |
| 6/30/2021 | 947 | -1,327 | -1,193 | -974 | N/A |
| 3/31/2021 | 863 | -1,167 | -1,030 | -816 | N/A |
| 12/31/2020 | 309 | -1,625 | -1,510 | -1,283 | N/A |
| 9/30/2020 | 266 | -1,512 | -1,426 | -1,218 | N/A |
| 6/30/2020 | 225 | -1,394 | -1,301 | -1,137 | N/A |
| 3/31/2020 | 402 | -1,145 | -1,093 | -920 | N/A |
| 12/31/2019 | 428 | -949 | -909 | -750 | N/A |
| 9/30/2019 | 430 | -829 | -876 | -677 | N/A |
| 6/30/2019 | 434 | -665 | -747 | -544 | N/A |
| 3/31/2019 | 244 | -737 | -787 | -615 | N/A |
| 12/31/2018 | 198 | -674 | -689 | -548 | N/A |
| 9/30/2018 | 158 | -505 | -344 | -260 | N/A |
| 6/30/2018 | 324 | -243 | -189 | -121 | N/A |
| 3/31/2018 | 271 | -147 | -129 | -56 | N/A |
| 12/31/2017 | 238 | -93 | -46 | 13 | N/A |
| 9/30/2017 | 220 | -31 | N/A | -107 | N/A |
| 6/30/2017 | N/A | -184 | N/A | -138 | N/A |
| 3/31/2017 | 0 | -148 | N/A | -105 | N/A |
| 12/31/2016 | 1 | -119 | N/A | -90 | N/A |
| 9/30/2016 | 6 | -109 | N/A | -80 | N/A |
| 6/30/2016 | 7 | -87 | N/A | -66 | N/A |
| 3/31/2016 | 8 | -69 | N/A | -56 | N/A |
| 12/31/2015 | 9 | -57 | N/A | -40 | N/A |
| 9/30/2015 | 6 | -34 | N/A | -34 | N/A |
| 6/30/2015 | 11 | -29 | N/A | -19 | N/A |
| 3/31/2015 | 12 | -26 | N/A | -11 | N/A |
| 12/31/2014 | 13 | -18 | N/A | -9 | N/A |
| 12/31/2013 | 11 | -7 | N/A | 4 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: BGNE is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.3%).
Earnings vs Market: BGNE is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: BGNE is expected to become profitable in the next 3 years.
Revenue vs Market: BGNE's revenue (19.4% per year) is forecast to grow faster than the US market (8% per year).
High Growth Revenue: BGNE's revenue (19.4% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: BGNE's Return on Equity is forecast to be low in 3 years time (13.6%).